Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar
Yıl: 2018 Cilt: 2 Sayı: 4 Sayfa Aralığı: 352 - 357 Metin Dili: Türkçe İndeks Tarihi: 24-05-2019
Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar
Öz: Behçet hastalığı etiyolojisi tam olarak bilinmeyen multisistemik bir vaskülittir. Göz tutulumu, özellikle de posterior segmenttutulumu hastalığın en yıkıcı klinik görünümüdür ve mutlak immünsüpresif tedavi endikasyonudur. Ancak konvansiyonelajanlarla yapılan immünsüpresyon üveit ataklarını ve dolayısıyla görme kaybını önlemede yetersiz olabilmektedir. Tedavininbir sonraki basamağını oluşturan interferonlar, antiviral, antiproliferatif ve immünmodülatör özelliklere sahip olansitokinlerdir. Behçet hastalığının göz tutulumunda oldukça etkilidirler. Tekrarlayan atakları önler ve görme prognozunuiyileştirirler. Maküler ödem ve retinal neovaskülarizasyonların tedavisinde başarıyla kullanılmaktadırlar. Ayrıca ilaçkesildikten sonra uzun dönemde remisyon sağlamaktadırlar. Bu derlemenin amacı interferonların etki mekanizmasını veBehçet üveitinin tedavisinde etkinliği ve güvenilirliğini özetlemektir.
Anahtar Kelime: Konular:
Interferons in the Treatment of Behçet Uveitis
Öz: Behçet disease is a multisystem vasculitis with unknown etiology. Ocular involvement, especially posterior segment involvement is the most devastating manifestation of the disease and is absolute indication for immunosuppressive treatment. However, immunosuppression with conventional agents may be inadequate to prevent destructive uveitis attacks and consequently visual loss. Interferons that constitute the next step of the treatment are the cytokines, which have antiviral, antiproliferative, and imunomodulatory features. They are quite effective in the treatment of Behçet uveitis. They prevent recurrent attacks and improve visual prognosis. They are used successfully in the treatment of macular edema and retinal neovascularizations. Furthermore they provide long-term remission after secession of interferon treatment. The aim of this review is to summarize the mechanism of action and the effectivity and safety of interferons in the treatment of Behçet uveitis.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik
- Zierhut M, Abu El-Asrar AM, Bodaghi B, et al. Therapy of ocular Behcet disease. Ocul Immunol Inflamm. 2014;22(1):64-76.
- Tugal-Tutkun I. Imaging in the diagnosis and management of Behcet disease. Int Ophthalmol Clin. 2012;52(4):183-90.
- Tugal-Tutkun I, Ozdal PC, Oray M, et al. Review for Diagnostics of the Year: Multimodal Imaging in Behcet Uveitis. Ocul Immunol Inflamm. 2017;25(1):7-19.
- Hazirolan D, Stubiger N, Pleyer U. Light on the horizont: biologicals in Behcet uveitis. Acta Ophthalmol. 2013;91(4):297-306.
- Tsambaos D, Eichelberg D, Goos M. Behcet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278(4):335- 6.
- Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320-35.
- Mesquida M, Molins B, Llorenc V, et al. Current and future treatments for Behcet’s uveitis: road to remission. Int Ophthalmol. 2014;34(2):365-81.
- Mackensen F, Max R, Becker MD. Interferon therapy for ocular disease. Curr Opin Ophthalmol. 2006;17(6):567-73.
- Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet’s disease. Rheumatology (Oxford). 2011;50(2):293-8.
- Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon- alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692-5.
- Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423-31.
- 1Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum. 2010;62(9):2796-805.
- Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129(3):288-94.
- Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146(6):837-44 e1.
- Diwo E, Gueudry J, Saadoun D, et al. Long-term Efficacy of Interferon in Severe Uveitis Associated with Behcet Disease. Ocul Immunol Inflamm. 2017;25(1):76-84.
- Kotter I, Zierhut M, Eckstein A, et al. Human recombinant interferon- alpha2a (rhIFN alpha2a) for the treatment of Behcet’s disease with sight- threatening retinal vasculitis. Adv Exp Med Biol. 2003;528:521-3.
- Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. Isr Med Assoc J. 2002;4(11 Suppl):928-30.
- Yalcindag FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet’s disease. J Ocul Pharmacol Ther. 2012;28(4):439-43.
- Hasanreisoglu M, Cubuk MO, Ozdek S, et al. Interferon Alpha-2a Therapy in Patients with Refractory Behcet Uveitis. Ocul Immunol Inflamm. 2017;25(1):71-5.
- Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet’s uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430-5.
- Kavandi H, Khabbazi A, Kolahi S, et al. Long-term efficacy and safety of interferon alpha-2a therapy in severe refractory ophthalmic Behcet’s disease. Clin Rheumatol. 2016;35(11):2765-9.
- Deuter CM, Koetter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26(7):786-91.
- Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478-86 e1.
- Deuter CM, Gelisken F, Stubiger N, et al. Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. Ocul Immunol Inflamm. 2011;19(3):216-8. Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm. 2012;20(2):86-90.
- Oray M, Onal S, Uludag G, et al. Interferon Alpha for the Treatment of Cystoid Macular Edema Associated with Presumed Ocular Tuberculosis. J Ocul Pharmacol Ther. 2017;33(4):304-12.
- Qian Z, Fardeau C, Cardoso JN, et al. Effect of interferon alpha2a in cystoid macular edema due to intraocular infection. Eur J Ophthalmol. 2015;25(5):431-6.
- Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-80.
- Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol. 2000;84(12):1437-8.
- Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Neovascularization of the optic disc in Behcet’s disease. Jpn J Ophthalmol. 2006;50(3):256-65.
- Raza A, Mittal S, Sood GK. Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review. J Viral Hepat. 2013;20(9):593-9.
- Aydinoglu-Candan O, Araz-Ersan B, Gul A, et al. Anti-interferon alpha antibodies and autoantibodies in patients with Behcet’s disease uveitis treated with recombinant human interferon alpha-2a. Graefes Arch Clin Exp Ophthalmol. 2015;253(3):457-65.
- Bielefeld P, Devilliers H, Deschasse C, et al. Potential of Pegylated Interferon Alpha-2a in Behcet Uveitis: A Report of Five Cases. Ocul Immunol Inflamm. 2016;24(5):599-602.
- Celiker H, Kazokoglu H, Direskeneli H. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behcet’s Uveitis: A Small Case Series. Ocul Immunol Inflamm. 2017:1-8.
- Narkewicz MR, Rosenthal P, Schwarz KB, et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr. 2010;51(2):183-6.
- Kang HY, Shin MC. Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis. Korean J Ophthalmol. 2012;26(2):147-50.
| APA | ESER ÖZTÜRK H, SÜLLÜ Y (2018). Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. , 352 - 357. |
| Chicago | ESER ÖZTÜRK HİLAL,SÜLLÜ Yüksel Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. (2018): 352 - 357. |
| MLA | ESER ÖZTÜRK HİLAL,SÜLLÜ Yüksel Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. , 2018, ss.352 - 357. |
| AMA | ESER ÖZTÜRK H,SÜLLÜ Y Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. . 2018; 352 - 357. |
| Vancouver | ESER ÖZTÜRK H,SÜLLÜ Y Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. . 2018; 352 - 357. |
| IEEE | ESER ÖZTÜRK H,SÜLLÜ Y "Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar." , ss.352 - 357, 2018. |
| ISNAD | ESER ÖZTÜRK, HİLAL - SÜLLÜ, Yüksel. "Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar". (2018), 352-357. |
| APA | ESER ÖZTÜRK H, SÜLLÜ Y (2018). Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. Güncel Retina Dergisi, 2(4), 352 - 357. |
| Chicago | ESER ÖZTÜRK HİLAL,SÜLLÜ Yüksel Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. Güncel Retina Dergisi 2, no.4 (2018): 352 - 357. |
| MLA | ESER ÖZTÜRK HİLAL,SÜLLÜ Yüksel Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. Güncel Retina Dergisi, vol.2, no.4, 2018, ss.352 - 357. |
| AMA | ESER ÖZTÜRK H,SÜLLÜ Y Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. Güncel Retina Dergisi. 2018; 2(4): 352 - 357. |
| Vancouver | ESER ÖZTÜRK H,SÜLLÜ Y Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar. Güncel Retina Dergisi. 2018; 2(4): 352 - 357. |
| IEEE | ESER ÖZTÜRK H,SÜLLÜ Y "Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar." Güncel Retina Dergisi, 2, ss.352 - 357, 2018. |
| ISNAD | ESER ÖZTÜRK, HİLAL - SÜLLÜ, Yüksel. "Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar". Güncel Retina Dergisi 2/4 (2018), 352-357. |
